Metrics manifesting the strongest concurrent validity with providers identified from these records related to those who co-prescribed benzodiazepines (e.g., valium) and high levels of opioid analgesics (e.g., oxycodone), as well as those who wrote temporally overlapping prescriptions. The report concludes with a discussion of a variety of uses to which these metrics may be put, as well as problems and opportunities related to their use. (Publisher abstract modified)
Downloads
Similar Publications
- 4F-MDMB-BINACA: A New Synthetic Cannabinoid Widely Implicated in Forensic Casework
- Body Fluid Identification Using a Targeted mRNA Massively Parallel Sequencing Approach - Results of a EUROFORGEN/EDNAP Collaborative Exercise
- GC-MS Studies on the Regioisomeric 2 3- and 3 4-Methylenedioxyphenethylamines Related to MDEA MDMMA and MBDB